Recombinant Human Growth Hormone in the Treatment of Children with Growth Hormone Deficiency

Chen Yuhui; Guo Yingchun

doi:10.13407/j.cnki.jpp.1672-108X.2020.10.008

您当前的位置：

首页 >

文章列表页 >

Recombinant Human Growth Hormone in the Treatment of Children with Growth Hormone Deficiency

更新时间：2022-11-03

- Recombinant Human Growth Hormone in the Treatment of Children with Growth Hormone Deficiency
- Vol. 26, Issue 10, Pages: 23-26(2020)
- 作者机构：
  
  南通大学附属常州儿童医院,江苏,常州,213000
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.10.008
  CLC：
- Published：2020，
  
  Published Online：10 October 2020，
扫描看全文
Chen Yuhui, Guo Yingchun. Recombinant Human Growth Hormone in the Treatment of Children with Growth Hormone Deficiency. [J]. 26(10):23-26(2020)
DOI：

Chen Yuhui, Guo Yingchun. Recombinant Human Growth Hormone in the Treatment of Children with Growth Hormone Deficiency. [J]. 26(10):23-26(2020) DOI： 10.13407/j.cnki.jpp.1672-108X.2020.10.008.

摘要

目的：探讨重组人生长激素（rhGH）对生长激素缺乏症（GHD）患儿的治疗效果及对甲状腺功能、血清胰岛素生长因子-1（IGF-1）、25羟维生素D（25（OH）D）水平的影响。方法：选取我院2013年1月至2017年12月我院门诊治疗的70例GHD患儿作为试验组，另外选取70名同龄健康儿童作为对照组，试验组采用rhGH治疗，分析试验组在治疗6个月、治疗12个月后的身高、身高标准差积分、生长速率、骨龄/实际年龄，检测试验组治疗前及治疗12个月后的血清游离三碘甲状腺原氨酸（FT3）、游离甲状腺激素（FT4）、促甲状腺激素（TSH）、IGF-1、25（OH）D水平，并与对照组进行比较。结果：在治疗6个月、12个月后，试验组患儿的身高、身高标准差积分、生长速率、骨龄/实际年龄测定值较治疗前均显著的增加，差异有统计学意义（P<0.05）；在治疗12个月后，试验组患儿的血清FT3、IGF-1、25（OH）D水平升高，差异具有统计学意义（P<0.05），对照组的血清FT3高于试验组治疗前水平（P<0.05），对照组的血清IGF-1、25（OH）D高于试验组治疗前及治疗后的水平（P<0.05）。结论：rhGH对GHD患儿的治疗效果显著，能明显改变患儿FT3、血清IGF-1、25（OH）D水平。

Abstract

Objective: To probe into the efficacy of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency (GHD) and its effects on the levels of thyroid function

serum insulin growth factor-1 (IGF-1) and 25-hydroxyvitamin D (25(OH)D). Methods: Seventy children with GHD admitted to our hospital from 2013 to 2017 were selected as the experimental group

and another 70 healthy children of the same age were selected as the control group. Serum levels of free triiodothyronine (FT3)

free thyroid hormone (FT4)

thyroid-stimulating hormone (TSH)

IGF-1 and 25(OH)D were detected in the experimental group before treatment and after treatment of 12 months

and compared with those in the control group. Results: After treatment of 6 and 12 months

the height

height standard deviation score

growth rate and bone age/actual age of the experimental group were significantly higher than those before treatment (P<0.05). After treatment of 12 months

the serum levels of FT3 in the experimental group increased significantly (P<0.05)

the serum levels of FT3 in the control group were higher than those in the experimental group before treatment (P<0.05). The serum levels of IGF-1 and 25(OH)D in the control group were significantly higher than those in the experimental group before and after treatment (P<0.05). Conclusion: The therapeutic effects of rhGH in the treatment of children with GHD was significant

which could significantly improve the levels of FT3 and serum IGF-1 and 25(OH)D in children.

关键词

重组人生长激素生长激素缺乏症甲状腺功能胰岛素生长因子-125羟维生素D

Keywords

recombinant human growth hormonegrowth hormone deficiencythyroid functionnsulin growth factor-125-hydroxyvitamin D

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules Combined with Recombinant Human Growth Hormone on Growth and Development of Children with Short Stature

Related Author

Chen Lijuan

Li Bin

Yang Lixin

Jing Xiaoqing

Related Institution

Affiliated Hospital of Chengde Medical College